Comparison of clinical characteristics of coronavirus disease (COVID-19) and severe acute respiratory syndrome (SARS) as experienced in Taiwan

Su, Yu‐Jang; Lai, Yen‐Chun

doi:10.1016/j.tmaid.2020.101625

Cited by 25 publications

(20 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There is currently limited information regarding youth and young adults, or in public health systems, during the pandemic [ 14 , 15 ]. This is likely due to lack of symptomatology on behalf of children [ 16 , 17 ] and lack of reporting or presentation at the time by young adults [ 18 ]. Severe consequences of a COVID-19 infection include respiratory distress [ 19 ], need for ventilator [ 20 ], tracheotomy [ 21 ], and sequential organ failure [ 22 , 23 ].…”

Section: Discussionmentioning

confidence: 99%

Characteristics, comorbidities and survival analysis of young adults hospitalized with COVID-19 in New York City

et al. 2020

View full text Add to dashboard Cite

This study reviewed 395 young adults, 18–35 year-old, admitted for COVID-19 to one of the eleven hospitals in New York City public health system. Demographics, comorbidities, clinical course, outcomes and characteristics linked to hospitalization were analyzed including temporal survival analysis. Fifty-seven percent of patients had a least one major comorbidity. Mortality without comorbidity was in 3.8% patients. Further investigation of admission features and medical history was conducted. Comorbidities associated with mortality were diabetes (n = 54 deceased/73 diagnosed,74% tested POS;98.2% with diabetic history deceased; Wilcoxon p (Wp) = .044), hypertension (14/44,32% POS, 25.5%; Wp = 0.030), renal (6/16, 37.5% POS,11%; Wp = 0.000), and cardiac (6/21, 28.6% POS,11%; Wp = 0.015). Kaplan survival plots were statistically significant for these four indicators. Data suggested glucose >215 or hemoglobin A1c >9.5 for young adults on admission was associated with increased mortality. Clinically documented respiratory distress on admission was statistically significant outcome related to mortality (X2 = 236.6842, df = 1, p < .0001). Overall, 28.9% required supportive oxygen beyond nasal cannula. Nasal cannula oxygen alone was required for 71.1%, who all lived. Non-invasive ventilation was required for 7.8%, and invasive mechanical ventilation 21.0% (in which 7.3% lived, 13.7% died). Temporal survival analysis demonstrated statistically significant response for Time to Death <10 days (X2 = 18.508, df = 1, p = .000); risk lessened considerably for 21 day cut off (X2 = 3.464, df = 1, p = .063), followed by 31 or more days of hospitalization (X2 = 2.212, df = 1, p = .137).

show abstract

Section: Discussionmentioning

confidence: 99%

Characteristics, comorbidities and survival analysis of young adults hospitalized with COVID-19 in New York City

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Su and Lai (24), reported the data of 10 confirmed cases till January 31st, 2020, and compared that data to SARS in terms of symptoms, epidemiology, and laboratory characteristics The research shows that there were 30% of males. The most common symptoms included cough in 60%, fever in 50%, flu symptoms in 40%, rhinorrhea in 30%, myalgia in 10%, and shortness of breath in 10% patients.…”

Section: A Study From Taiwanmentioning

confidence: 99%

Comparison of Epidemiological Variations in COVID-19 Patients Inside and Outside of China—A Meta-Analysis

Ahmed

Ali

Hasan

2020

Front. Public Health

View full text Add to dashboard Cite

show abstract

“…However, these molecules could not be taken to clinical trials since there were not enough patients suffering from SARS virus by the time these drugs were developed. Nevertheless, this information is of tremendous use since SARS-CoV and SARS-CoV-2 share striking similarities in the genome, replication cycle and even symptoms experienced by patients (Su and Lai 2020). Systemic genomic comparisons have revealed a striking 79% similarity at the nucleotide level between SARS-CoV-2 and SARS-CoV.…”

Section: Current Efforts From Top Pharmaceutical Companiesmentioning

confidence: 99%

Drug targets for COVID-19 therapeutics: Ongoing global efforts

Saxena

2020

J Biosci

View full text Add to dashboard Cite

The current global pandemic COVID-19 caused by the SARS-CoV-2 virus has already inflicted insurmountable damage both to the human lives and global economy. There is an immediate need for identification of effective drugs to contain the disastrous virus outbreak. Global efforts are already underway at a war footing to identify the best drug combination to address the disease. In this review, an attempt has been made to understand the SARS-CoV-2 life cycle, and based on this information potential druggable targets against SARS-CoV-2 are summarized. Also, the strategies for ongoing and future drug discovery against the SARS-CoV-2 virus are outlined. Given the urgency to find a definitive cure, ongoing drug repurposing efforts being carried out by various organizations are also described. The unprecedented crisis requires extraordinary efforts from the scientific community to effectively address the issue and prevent further loss of human lives and health.

show abstract

Comparison of clinical characteristics of coronavirus disease (COVID-19) and severe acute respiratory syndrome (SARS) as experienced in Taiwan

Cited by 25 publications

References 3 publications

Characteristics, comorbidities and survival analysis of young adults hospitalized with COVID-19 in New York City

Characteristics, comorbidities and survival analysis of young adults hospitalized with COVID-19 in New York City

Comparison of Epidemiological Variations in COVID-19 Patients Inside and Outside of China—A Meta-Analysis

Drug targets for COVID-19 therapeutics: Ongoing global efforts

Contact Info

Product

Resources

About